Thomas D B, Whysner J A, Newmann M C
NIDA Res Monogr. 1979;27:289-295b.
Two essential points can be made: 1. Mortality experience in the LAAM Phase II trial follows closely the experience of methadone maintenance though these data should be considered preliminary. 2. Generally, the influence of time in treatment on the probability of mortality is strong enough to warrant avoiding comparisons between mortality rates where this parameter is not controlled.
